Helio Genomics CEO Justin Li discussed the company’s advancements in precision cancer diagnostics, particularly highlighting their AI-driven platform MESA for colorectal cancer screening. The platform combines cfDNA methylation analysis with machine learning, achieving high sensitivity. Helio’s flagship product, HelioLiver, has shown superior performance in detecting early-stage liver cancer compared to traditional methods. The company is also exploring applications in other cancers and plans to expand into deep learning and generative AI.
Full interview is available on Percision Medicine Online
To learn more about Helio Genomics, please visit heliogenomics.com